HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.

Rinnerthaler, Gabriel; Gampenrieder, Simon Peter; Greil, Richard

Rinnerthaler, Gabriel; Gampenrieder, Simon Peter; Greil, Richard.

Affiliation

Rinnerthaler G; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, 5020 Salzburg,
Gampenrieder SP; Cancer Cluster Salzburg, 5020 Salzburg, Austria. g.rinnerthaler@salk.at.
Greil R; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, 5020 Salzburg,

Int J Mol Sci ; 20(5)2019 Mar 05.

Article in En | MEDLINE | ID: mdl-30841523

Subject(s)
Key words

(vic-)trastuzumab duocarmazine; ADC; HER2 low; HM2-MMAE; TAK-522; Trastuzumab deruxtecan; Trastuzumab emtansine; anti-HER2/PBD-MA; mode of action

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Protein Kinase Inhibitors / Trastuzumab / Antineoplastic Agents, Immunological / Maytansine Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Int J Mol Sci Year: 2019 Document type: Article Country of publication: Suiza

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google